LL-37

Overview

It's completely reasonable — and intelligent — to be curious about LL-37.

LL-37 is the C-terminal 37-amino-acid peptide produced by proteolytic cleavage of hCAP-18, the only cathelicidin antimicrobial peptide in humans. It is widely expressed in skin, mucosa, and immune cells, where it functions as a first-line antimicrobial defense molecule and as a signaling peptide in tissue repair and immune modulation.

People researching LL-37 are typically trying to understand how innate immunity, chronic wound biology, and inflammatory skin conditions connect — and what it means that one peptide does all of this.

The Science: A Swiss-Army Antimicrobial

Think of LL-37 as a pocket-knife peptide: one molecule with several distinct functions that evolved to work together.

• Direct antimicrobial activity: LL-37 disrupts bacterial, fungal, and viral membranes through an amphipathic α-helical structure that inserts into lipid bilayers — a mechanism less prone to classical antibiotic resistance than target-specific antibiotics.
• Antibiofilm activity: Effective at concentrations below minimum inhibitory concentration against several biofilm-forming organisms, relevant to chronic wound and device-associated infections.
• Chemotaxis and immunomodulation: Acts as a chemoattractant for neutrophils, monocytes, and T cells, and modulates cytokine production at sites of infection.
• Wound-healing signaling: Promotes keratinocyte migration, angiogenesis, and re-epithelialization beyond its antimicrobial role.
• DNA-peptide complexes: Interaction with self-DNA in autoimmune contexts (notably psoriasis) links LL-37 to type I interferon induction — a reminder that the same peptide can be protective in one context and pathogenic in another.

What Researchers Have Observed

The evidence base spans preclinical biology and some early clinical work:

• Chronic wound healing: A Phase 2 trial in hard-to-heal venous leg ulcers reported improved healing with topical LL-37, motivating continued clinical development.
• Skin infection and inflammation: Preclinical studies examine LL-37 in atopic dermatitis, acne, and rosacea, where endogenous LL-37 levels are dysregulated.
• Antibiofilm therapeutics: Particularly for diabetic foot ulcers, osteomyelitis, and medical-device infections, LL-37 and its analogs are studied as adjuncts or alternatives to conventional antibiotics.
• Respiratory infections: Research interest in inhaled LL-37 for cystic fibrosis and bacterial pneumonia, leveraging its antimicrobial breadth.
• Oral and periodontal health: Mucosal immunity research covers LL-37's role in oral defense.

The Empowerment Angle: Quality of Life Research

Many people researching LL-37 aren't looking for a shortcut around antibiotics. They're exploring:

• How innate immunity actually works — a surprisingly under-taught area of human biology
• Why chronic wounds are so difficult and what makes a wound "stuck"
• The relationship between skin, microbiome, and inflammation — relevant to a long list of quality-of-life conditions
• How antibiotic resistance is reshaping infection research and where host-defense peptides fit
• Their own skin or wound biology with a more informed framework

Learning about cathelicidins, defensins, keratinocyte biology, and the interplay of antimicrobial and signaling functions gives LL-37 research real depth.

State of the Evidence

LL-37 has a well-characterized mechanistic base and a meaningful early-clinical presence:

• Well-characterized basic biology
• Phase 2 clinical data in chronic venous leg ulcers
• Commercial development has been pursued by several groups (including Promore Pharma's wound-healing programs)
• Not FDA-approved
• Context-dependent effects: elevated LL-37 contributes to psoriasis and lupus pathogenesis in some contexts — a reminder that endogenous antimicrobial peptides are not universally beneficial

This context-dependence is part of what makes LL-37 such a rich research target — it's not a simple "good peptide" or "bad peptide" story.

Approaching Research Responsibly

If you're researching this compound, the most grounded approach combines curiosity with care:

The most mature approach isn't blind optimism or reflexive skepticism, but curious, methodical, well-informed self-experimentation.

This entry is designed to help you understand both the science and the human motivation behind researching LL-37. The goal is informed curiosity and empowerment, not medical advice.

References

1. [1]Vandamme D et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide(2012) · doi:10.1016/j.cellimm.2012.02.008
2. [2]Grönberg A et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers(2014) · doi:10.1111/wrr.12176
3. [3]Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease(2013) · doi:10.4049/jimmunol.1302005